33 results
8-K
EX-1.1
VERV
Verve Therapeutics Inc
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
as a preventative measure similar to the way that certain vaccines offer long-term protection against infectious diseases.
VERVE-101
Our lead product … base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. In a long-term preclinical study of VERVE-101 in non-human
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
as a preventative measure similar to the way that certain vaccines offer long-term protection against infectious diseases.
VERVE-101
Our lead product … change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. In a long-term preclinical study of VERVE-101 in non-human
8-K
EX-1.1
b3b7c
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
424B5
bewsati
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
matflm1uenl8sp5ywg8h
20 Jul 22
Prospectus supplement for primary offering
4:22pm
S-3
EX-1.2
2pp0df 22
1 Jul 22
Shelf registration
4:36pm
8-K
EX-99.1
z9d6oc6i 6aew
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
DEF 14A
pkf9m
29 Apr 22
Definitive proxy
7:01am
10-K
s65 3xkebdcxlj74vzrd
14 Mar 22
Annual report
7:04am
8-K
EX-99.1
pf3rylo vvp35yz
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am